This program is designed to update participants on the latest advances in the diagnosis and treatment of thyroid eye disease (TED), a complex and potentially sight-threatening condition. Current evidence and best practices for managing TED with novel biologic therapies, such as teprotumumab, rituximab, and tocilizumab, will be presented. Participants will also be given practical tips on how to identify and manage treatment-related adverse effects, such as hearing impairment and hyperglycemia, and how to collaborate effectively with a multidisciplinary team of specialists. This program offers participants an opportunity to enhance their knowledge and skills in treating TED in order to improve their patients quality of life.
- Provider:MedEdicus, LLC
- Activity Link: https://courses.mededicus.com
- Start Date: 2024-06-01 05:00:00
- End Date: 2024-06-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: Amgen, Inc. - Amount: 213400.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest